Review



assays fibroblast growth factor 21 human elisa biovendor  (BioVendor Instruments)


Bioz Verified Symbol BioVendor Instruments is a verified supplier
Bioz Manufacturer Symbol BioVendor Instruments manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    BioVendor Instruments assays fibroblast growth factor 21 human elisa biovendor
    Assays Fibroblast Growth Factor 21 Human Elisa Biovendor, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 94/100, based on 90 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibroblast+growth+factor+21+human+elisa/pm41920739-171-137-144?v=BioVendor+Instruments
    Average 94 stars, based on 90 article reviews
    assays fibroblast growth factor 21 human elisa biovendor - by Bioz Stars, 2026-08
    94/100 stars

    Images



    Similar Products

    94
    BioVendor Instruments assays fibroblast growth factor 21 human elisa biovendor
    Assays Fibroblast Growth Factor 21 Human Elisa Biovendor, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibroblast+growth+factor+21+human+elisa/pm41920739-171-137-144?v=BioVendor+Instruments
    Average 94 stars, based on 1 article reviews
    assays fibroblast growth factor 21 human elisa biovendor - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    92
    Cusabio human fgf21 elisa kit
    Human Fgf21 Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibroblast+growth+factor+21+human+elisa/pm41862050-82-19-23?v=Cusabio
    Average 92 stars, based on 1 article reviews
    human fgf21 elisa kit - by Bioz Stars, 2026-08
    92/100 stars
      Buy from Supplier

    94
    BioVendor Instruments fibroblast growth factor 21 human elisa
    Fibroblast Growth Factor 21 Human Elisa, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibroblast+growth+factor+21+human+elisa/pm41192720-93-41-47?v=BioVendor+Instruments
    Average 94 stars, based on 1 article reviews
    fibroblast growth factor 21 human elisa - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    94
    BioVendor Instruments sandwich elisa
    Sandwich Elisa, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibroblast+growth+factor+21+human+elisa/pm41093925-97-6-8?v=BioVendor+Instruments
    Average 94 stars, based on 1 article reviews
    sandwich elisa - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    94
    BioVendor Instruments fgf21 human elisa kit
    Fgf21 Human Elisa Kit, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibroblast+growth+factor+21+human+elisa/pmc12501196-117-19-18?v=BioVendor+Instruments
    Average 94 stars, based on 1 article reviews
    fgf21 human elisa kit - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    94
    BioVendor Instruments fgf21
    Fgf21, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibroblast+growth+factor+21+human+elisa/pm40828431-65-9-11?v=BioVendor+Instruments
    Average 94 stars, based on 1 article reviews
    fgf21 - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology fgf21 level
    Fibroblast growth factor 21 <t>(FGF21)</t> expression was significantly down-regulated in neointimal hyperplasia. (A) Paraffin sections of the carotid artery were prepared and used to determine the expression of FGF21 and smooth muscle 22α (SM22α) by immunofluorescence staining ( n = 3). Bars: 250 μm. (B) Plasma FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) in atherosclerotic coronary artery disease (ASCAD) patients and non-ASCAD patients ( n = 28). (C) FGF21 levels in the plasma of patients who underwent percutaneous coronary intervention (PCI) with and without restenosis were determined via ELISA ( n = 11). (D to F) Carotid artery ligation was performed in wild-type (WT) mice. Serum FGF21 levels were determined by ELISA ( n = 7) (D). FGF21 messenger RNA (mRNA) expression was determined by quantitative polymerase chain reaction (qPCR) ( n = 5) (E). The control and ligated carotid artery cross-sections were subjected to immunofluorescence staining to determine FGF21 and smooth muscle α-actin (SMA) expression ( n = 5) (F). Data information: Data are expressed as mean ± SD. Student t test, * P < 0.05. MFI, mean fluorescence intensity.
    Fgf21 Level, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibroblast+growth+factor+21+human+elisa/pmc12324144-228-8-19?v=Elabscience+Biotechnology
    Average 93 stars, based on 1 article reviews
    fgf21 level - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    Image Search Results


    Fibroblast growth factor 21 (FGF21) expression was significantly down-regulated in neointimal hyperplasia. (A) Paraffin sections of the carotid artery were prepared and used to determine the expression of FGF21 and smooth muscle 22α (SM22α) by immunofluorescence staining ( n = 3). Bars: 250 μm. (B) Plasma FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) in atherosclerotic coronary artery disease (ASCAD) patients and non-ASCAD patients ( n = 28). (C) FGF21 levels in the plasma of patients who underwent percutaneous coronary intervention (PCI) with and without restenosis were determined via ELISA ( n = 11). (D to F) Carotid artery ligation was performed in wild-type (WT) mice. Serum FGF21 levels were determined by ELISA ( n = 7) (D). FGF21 messenger RNA (mRNA) expression was determined by quantitative polymerase chain reaction (qPCR) ( n = 5) (E). The control and ligated carotid artery cross-sections were subjected to immunofluorescence staining to determine FGF21 and smooth muscle α-actin (SMA) expression ( n = 5) (F). Data information: Data are expressed as mean ± SD. Student t test, * P < 0.05. MFI, mean fluorescence intensity.

    Journal: Research

    Article Title: Fibroblast Growth Factor 21 Promotes Vascular Smooth Muscle Cell Contractile Polarization via p38 Mitogen-Activated Protein Kinase-Promoted Serum Response Factor Phosphorylation

    doi: 10.34133/research.0815

    Figure Lengend Snippet: Fibroblast growth factor 21 (FGF21) expression was significantly down-regulated in neointimal hyperplasia. (A) Paraffin sections of the carotid artery were prepared and used to determine the expression of FGF21 and smooth muscle 22α (SM22α) by immunofluorescence staining ( n = 3). Bars: 250 μm. (B) Plasma FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) in atherosclerotic coronary artery disease (ASCAD) patients and non-ASCAD patients ( n = 28). (C) FGF21 levels in the plasma of patients who underwent percutaneous coronary intervention (PCI) with and without restenosis were determined via ELISA ( n = 11). (D to F) Carotid artery ligation was performed in wild-type (WT) mice. Serum FGF21 levels were determined by ELISA ( n = 7) (D). FGF21 messenger RNA (mRNA) expression was determined by quantitative polymerase chain reaction (qPCR) ( n = 5) (E). The control and ligated carotid artery cross-sections were subjected to immunofluorescence staining to determine FGF21 and smooth muscle α-actin (SMA) expression ( n = 5) (F). Data information: Data are expressed as mean ± SD. Student t test, * P < 0.05. MFI, mean fluorescence intensity.

    Article Snippet: We isolated plasma from blood samples, and the FGF21 level was measured using an ELISA kit (Cat. No. E-EL-H0074, Elabscience Biotechnology Co., Ltd.).

    Techniques: Expressing, Immunofluorescence, Staining, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Ligation, Real-time Polymerase Chain Reaction, Control, Fluorescence

    FGF21 inhibits neointimal formation by binding to its receptor in the aorta. (A and B) Carotid artery ligation ( n = 5) and femoral artery guidewire injury ( n = 7) were performed in WT and FGF21 −/− mice. Both the left and right carotid arteries and the femoral artery were collected, and cross-sections were prepared for hematoxylin and eosin (HE) staining for morphological analysis with quantitative analysis of the neointima and media areas. Data information: Data are expressed as mean ± SD. Student t test, * P < 0.05. (C and D) Left carotid artery ligation was performed on female C57BL/6J and FGF21 −/− mice ( n = 8), and FGF21 −/− mice were intravenously injected with recombinant mouse FGF21 protein (rmFGF21; 600 μg/kg) twice a week for 4 weeks. At the end of the experiment, carotid artery samples were individually collected and used for the following assay: (C) HE staining for morphological analysis with quantitative analysis of neointima and media areas. (D) The expression of SMA and SM22α in neointimal areas was determined by immunofluorescence staining. (E and F) Female KLB f/f and KLB SMKO mice ( n = 6) were subjected to left carotid artery ligation, and rmFGF21 (600 μg/kg) was intravenously injected twice a week for 4 weeks. At the end of the experiment, carotid artery samples were individually collected and used for the following assay: (E) HE staining for morphological analysis with quantitative analysis of neointima and media areas. (F) The expression of SMA and osteopontin (OPN) in neointimal areas was determined by immunofluorescence staining ( n = 5). Data information: The data are expressed as mean ± SD. Student t test (2 groups), 1-way analysis of variance (ANOVA) or 2-way ANOVA followed by Tukey’s test (more than 2 groups), * P < 0.05; ns, not significant. RCA, right carotid artery; LCA, left carotid artery; PBS, phosphate-buffered saline; i.v., intravenous.

    Journal: Research

    Article Title: Fibroblast Growth Factor 21 Promotes Vascular Smooth Muscle Cell Contractile Polarization via p38 Mitogen-Activated Protein Kinase-Promoted Serum Response Factor Phosphorylation

    doi: 10.34133/research.0815

    Figure Lengend Snippet: FGF21 inhibits neointimal formation by binding to its receptor in the aorta. (A and B) Carotid artery ligation ( n = 5) and femoral artery guidewire injury ( n = 7) were performed in WT and FGF21 −/− mice. Both the left and right carotid arteries and the femoral artery were collected, and cross-sections were prepared for hematoxylin and eosin (HE) staining for morphological analysis with quantitative analysis of the neointima and media areas. Data information: Data are expressed as mean ± SD. Student t test, * P < 0.05. (C and D) Left carotid artery ligation was performed on female C57BL/6J and FGF21 −/− mice ( n = 8), and FGF21 −/− mice were intravenously injected with recombinant mouse FGF21 protein (rmFGF21; 600 μg/kg) twice a week for 4 weeks. At the end of the experiment, carotid artery samples were individually collected and used for the following assay: (C) HE staining for morphological analysis with quantitative analysis of neointima and media areas. (D) The expression of SMA and SM22α in neointimal areas was determined by immunofluorescence staining. (E and F) Female KLB f/f and KLB SMKO mice ( n = 6) were subjected to left carotid artery ligation, and rmFGF21 (600 μg/kg) was intravenously injected twice a week for 4 weeks. At the end of the experiment, carotid artery samples were individually collected and used for the following assay: (E) HE staining for morphological analysis with quantitative analysis of neointima and media areas. (F) The expression of SMA and osteopontin (OPN) in neointimal areas was determined by immunofluorescence staining ( n = 5). Data information: The data are expressed as mean ± SD. Student t test (2 groups), 1-way analysis of variance (ANOVA) or 2-way ANOVA followed by Tukey’s test (more than 2 groups), * P < 0.05; ns, not significant. RCA, right carotid artery; LCA, left carotid artery; PBS, phosphate-buffered saline; i.v., intravenous.

    Article Snippet: We isolated plasma from blood samples, and the FGF21 level was measured using an ELISA kit (Cat. No. E-EL-H0074, Elabscience Biotechnology Co., Ltd.).

    Techniques: Binding Assay, Ligation, Staining, Injection, Recombinant, Expressing, Immunofluorescence, Saline

    FGF21 promotes vascular smooth muscle cell (VSMC) contractile phenotype switching through up-regulation of serum response factor (SRF) and myocardin (MYOCD). Human aortic smooth muscle cells (HASMCs) were transfected with pCMV-hemagglutinin (HA)/HA-FGF21 or siCtrl/siFGF21 for 24 h in serum-free medium and cultured with complete medium for 24 h. Then, the HASMCs were harvested and mixed with collagen at a ratio of 1:4 for another 48 h, after which the size of the collagen gel was evaluated ( n = 3) (A). FGF21, SMA, SM22α, myosin heavy chain 11 (MYH11), and calponin 1 (CNN1) mRNA levels were determined by qPCR ( n = 3) (B and E); FGF21, SMA, CNN1, SM22α, and OPN protein expression was determined by Western blotting ( n = 3) (C and F). (D) HASMCs were treated with recombinant human FGF21 (rhFGF21) protein (0.5 mg/ml) in serum-free medium for 24 h. The protein expression of FGF21, SM22α, SMA, and CNN1 was determined by Western blotting ( n = 3). (G to J) HASMCs in a 6-well plate were transfected with pCMV-HA/HA-FGF21 or siCtrl/siFGF21 for 24 h. Then, the cells were treated with or without platelet-derived growth factor-BB (PDGF-BB; 40 ng/ml) or heparin (100 μg/ml) for 24 h. The expression of SRF and MYOCD was determined by Western blotting ( n = 3). (K) The expression of SRF and MYOCD in the left carotid artery was determined by immunofluorescence staining and quantification of the MFI ( n = 5). (L and M) HASMCs in a 6-well plate were transfected with siCtrl/siFGF21 and HA-SRF or HA-MYOCD for 24 h. The expression of HA, SM22α, CNN1, and SMA was determined by Western blotting ( n = 3). Data information: Data are expressed as mean ± SD. Student t test (2 groups) or one-way ANOVA followed by Tukey’s test (more than 2 groups), * P < 0.05.

    Journal: Research

    Article Title: Fibroblast Growth Factor 21 Promotes Vascular Smooth Muscle Cell Contractile Polarization via p38 Mitogen-Activated Protein Kinase-Promoted Serum Response Factor Phosphorylation

    doi: 10.34133/research.0815

    Figure Lengend Snippet: FGF21 promotes vascular smooth muscle cell (VSMC) contractile phenotype switching through up-regulation of serum response factor (SRF) and myocardin (MYOCD). Human aortic smooth muscle cells (HASMCs) were transfected with pCMV-hemagglutinin (HA)/HA-FGF21 or siCtrl/siFGF21 for 24 h in serum-free medium and cultured with complete medium for 24 h. Then, the HASMCs were harvested and mixed with collagen at a ratio of 1:4 for another 48 h, after which the size of the collagen gel was evaluated ( n = 3) (A). FGF21, SMA, SM22α, myosin heavy chain 11 (MYH11), and calponin 1 (CNN1) mRNA levels were determined by qPCR ( n = 3) (B and E); FGF21, SMA, CNN1, SM22α, and OPN protein expression was determined by Western blotting ( n = 3) (C and F). (D) HASMCs were treated with recombinant human FGF21 (rhFGF21) protein (0.5 mg/ml) in serum-free medium for 24 h. The protein expression of FGF21, SM22α, SMA, and CNN1 was determined by Western blotting ( n = 3). (G to J) HASMCs in a 6-well plate were transfected with pCMV-HA/HA-FGF21 or siCtrl/siFGF21 for 24 h. Then, the cells were treated with or without platelet-derived growth factor-BB (PDGF-BB; 40 ng/ml) or heparin (100 μg/ml) for 24 h. The expression of SRF and MYOCD was determined by Western blotting ( n = 3). (K) The expression of SRF and MYOCD in the left carotid artery was determined by immunofluorescence staining and quantification of the MFI ( n = 5). (L and M) HASMCs in a 6-well plate were transfected with siCtrl/siFGF21 and HA-SRF or HA-MYOCD for 24 h. The expression of HA, SM22α, CNN1, and SMA was determined by Western blotting ( n = 3). Data information: Data are expressed as mean ± SD. Student t test (2 groups) or one-way ANOVA followed by Tukey’s test (more than 2 groups), * P < 0.05.

    Article Snippet: We isolated plasma from blood samples, and the FGF21 level was measured using an ELISA kit (Cat. No. E-EL-H0074, Elabscience Biotechnology Co., Ltd.).

    Techniques: Transfection, Cell Culture, Expressing, Western Blot, Recombinant, Derivative Assay, Immunofluorescence, Staining

    FGF21 promotes phosphorylation of the SRF Ser224 site by p38 mitogen-activated protein kinase (p38 MAPK), which in turn promotes recruitment of downstream contractile genes. (A) HASMCs in a 6-well plate were transfected with pCMV-HA/HA-FGF21 for 24 h. The expression of p38 MAPK and p-p38 MAPK was determined by Western blotting ( n = 3). (B) The expression of p38 MAPK and p-p38 MAPK in the aortas of the WT and FGF21 −/− mice subjected to carotid artery ligation was determined by Western blotting ( n = 3). (C and D) HASMCs were transfected with pCMV-HA or HA-FGF21 for 24 h in serum-free medium. Then, the cells were treated with SB203580 (10 μmol/l) for 12 h. The expression of SRF, MYOCD, p38 MAPK, p-p38 MAPK, SMA, CNN1, and SM22α was determined by Western blotting ( n = 3). (E) HASMCs were transfected with pCMV-HA or HA-MYOCD for 24 h, after which the cells were transferred to complete medium for 24 h. The resulting cell lysates were subjected to immunoprecipitation (IP) with anti-p-p38 MAPK, anti-SRF, or anti-MYOCD antibodies. The pulled-down complexes and input cell lysates were analyzed by Western blotting with the anti-p-p38 MAPK, anti-SRF, or anti-MYOCD antibodies. (F) HASMCs were transfected with pCMV-HA, HA-SRF, or HA-SRF plus siFGF21 for 24 h in serum-free medium, after which the cells were switched to complete medium for 24 h. The IP experiment was performed with HA-tagged magnetic beads, followed by immunoblotting with anti-MYOCD, SRF, and p38 MAPK antibodies ( n = 3). (G) Chromatin was isolated from HASMCs with or without rhFGF21 treatment (0.5 mg/ml). After determination of input, IP was conducted with normal immunoglobulin G (IgG) or SRF antibodies, followed by qPCR. * P < 0.05 versus the corresponding control ( n = 3). (H) HASMCs were transfected with pCMV-HA or HA-SRF for 24 h in serum-free medium, after which the cells were switched to complete medium and cultured for 24 h. An IP experiment was performed with HA-tagged magnetic beads, followed by immunoblotting with anti-phospho-serine or anti-phospho-threonine antibody. (I) HASMCs were transfected with pCMV-HA or HA-FGF21 for 24 h in serum-free medium, after which the cells were switched to complete medium and cultured for 24 h. IP experiments were performed with protein A/G magnetic beads, IgG, and anti-SRF antibody, followed by immunoblotting with anti-phospho-serine and anti-SRF antibodies. (J) Molecular docking of SRF and p38 MAPK proteins. (K and L) HASMCs were transfected with HA-SRF for 24 h in serum-free medium, after which the cells were switched to complete medium supplemented with anisomycin for 24 h. The cell lysate was separated via sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). The band corresponding to the molecular weight of SRF was cut and digested to carry out a liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay. (M) HASMCs were transfected with HA-SRF, HA-SRF S224A, or HA-SRF S224D for 24 h in serum-free medium, after which the cells were switched to complete medium for 24 h. The protein expression of SRF, MYOCD, HA, SMA, SM22α, CNN1, and OPN was determined by Western blotting ( n = 3). Data information: Data are expressed as mean ± SD. Student t test (2 groups) or one-way ANOVA followed by Tukey’s test (more than 2 groups), * P < 0.05; ns, not significant. IB, immunoblotting.

    Journal: Research

    Article Title: Fibroblast Growth Factor 21 Promotes Vascular Smooth Muscle Cell Contractile Polarization via p38 Mitogen-Activated Protein Kinase-Promoted Serum Response Factor Phosphorylation

    doi: 10.34133/research.0815

    Figure Lengend Snippet: FGF21 promotes phosphorylation of the SRF Ser224 site by p38 mitogen-activated protein kinase (p38 MAPK), which in turn promotes recruitment of downstream contractile genes. (A) HASMCs in a 6-well plate were transfected with pCMV-HA/HA-FGF21 for 24 h. The expression of p38 MAPK and p-p38 MAPK was determined by Western blotting ( n = 3). (B) The expression of p38 MAPK and p-p38 MAPK in the aortas of the WT and FGF21 −/− mice subjected to carotid artery ligation was determined by Western blotting ( n = 3). (C and D) HASMCs were transfected with pCMV-HA or HA-FGF21 for 24 h in serum-free medium. Then, the cells were treated with SB203580 (10 μmol/l) for 12 h. The expression of SRF, MYOCD, p38 MAPK, p-p38 MAPK, SMA, CNN1, and SM22α was determined by Western blotting ( n = 3). (E) HASMCs were transfected with pCMV-HA or HA-MYOCD for 24 h, after which the cells were transferred to complete medium for 24 h. The resulting cell lysates were subjected to immunoprecipitation (IP) with anti-p-p38 MAPK, anti-SRF, or anti-MYOCD antibodies. The pulled-down complexes and input cell lysates were analyzed by Western blotting with the anti-p-p38 MAPK, anti-SRF, or anti-MYOCD antibodies. (F) HASMCs were transfected with pCMV-HA, HA-SRF, or HA-SRF plus siFGF21 for 24 h in serum-free medium, after which the cells were switched to complete medium for 24 h. The IP experiment was performed with HA-tagged magnetic beads, followed by immunoblotting with anti-MYOCD, SRF, and p38 MAPK antibodies ( n = 3). (G) Chromatin was isolated from HASMCs with or without rhFGF21 treatment (0.5 mg/ml). After determination of input, IP was conducted with normal immunoglobulin G (IgG) or SRF antibodies, followed by qPCR. * P < 0.05 versus the corresponding control ( n = 3). (H) HASMCs were transfected with pCMV-HA or HA-SRF for 24 h in serum-free medium, after which the cells were switched to complete medium and cultured for 24 h. An IP experiment was performed with HA-tagged magnetic beads, followed by immunoblotting with anti-phospho-serine or anti-phospho-threonine antibody. (I) HASMCs were transfected with pCMV-HA or HA-FGF21 for 24 h in serum-free medium, after which the cells were switched to complete medium and cultured for 24 h. IP experiments were performed with protein A/G magnetic beads, IgG, and anti-SRF antibody, followed by immunoblotting with anti-phospho-serine and anti-SRF antibodies. (J) Molecular docking of SRF and p38 MAPK proteins. (K and L) HASMCs were transfected with HA-SRF for 24 h in serum-free medium, after which the cells were switched to complete medium supplemented with anisomycin for 24 h. The cell lysate was separated via sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). The band corresponding to the molecular weight of SRF was cut and digested to carry out a liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay. (M) HASMCs were transfected with HA-SRF, HA-SRF S224A, or HA-SRF S224D for 24 h in serum-free medium, after which the cells were switched to complete medium for 24 h. The protein expression of SRF, MYOCD, HA, SMA, SM22α, CNN1, and OPN was determined by Western blotting ( n = 3). Data information: Data are expressed as mean ± SD. Student t test (2 groups) or one-way ANOVA followed by Tukey’s test (more than 2 groups), * P < 0.05; ns, not significant. IB, immunoblotting.

    Article Snippet: We isolated plasma from blood samples, and the FGF21 level was measured using an ELISA kit (Cat. No. E-EL-H0074, Elabscience Biotechnology Co., Ltd.).

    Techniques: Phospho-proteomics, Transfection, Expressing, Western Blot, Ligation, Immunoprecipitation, Magnetic Beads, Isolation, Control, Cell Culture, Polyacrylamide Gel Electrophoresis, SDS Page, Molecular Weight, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy

    FGF21 activates p38 MAPK through the β-klotho (KLB)/FGFR1–transforming growth factor-β-activated kinase 1 (TAK1)–mitogen-activated protein kinase kinase 3/6 (MKK3/6) pathway. HASMCs were transfected with pCMV-HA or HA-FGF21 for 24 h, after which the cells were switched to complete medium for 24 h. The expression of p38 MAPK, p-p38 MAPK, FGFR1, p-FGFR1, and KLB in (A) or MKK3/6, p-MKK3/6, TAK1, and p-TAK1 in (D) was detected by Western blotting ( n = 3). (B and C) HASMCs were transfected with pCMV-HA or HA-FGF21 for 24 h. Then, the cells were treated with PD173074 (10 nmol/l) for 24 h. The expression of p-FGFR1, FGFR1, p-p38 MAPK, and p38 MAPK (B) and MYOCD, SRF, SMA, SM22α, and CNN1 (C) was determined by Western blotting ( n = 3). (E and F) After HA-FGF21 transfection for 24 h, HASMCs were treated with NG25 (10 μmol/l) for 24 h. The expression of p-TAK1, TAK1, p-MKK3/6, MKK3/6, p-p38 MAPK, and p38 MAPK (E) and SMA, SM22α, CNN1, MYOCD, and SRF (F) was determined by Western blotting ( n = 3). (G) HASMCs were transfected with HA-FGF21 for 24 h, followed by culture in complete medium for 24 h. The cell lysates were subjected to immunoprecipitation with anti-p-FGFR1 or anti-p-TAK1 antibodies. The pulled-down complexes and input cell lysates were analyzed by Western blotting with the anti-p-FGFR1 or anti-p-TAK1 antibodies. (H) Diagram of FGF21-activated p38 MAPK through the KLB/FGFR1–TAK1–MKK3/6 pathway. Data information: Data are expressed as mean ± SD. Student t test (2 groups) or 1-way ANOVA or 2-way ANOVA followed by Tukey’s test (more than 2 groups), * P < 0.05; ns, not significant.

    Journal: Research

    Article Title: Fibroblast Growth Factor 21 Promotes Vascular Smooth Muscle Cell Contractile Polarization via p38 Mitogen-Activated Protein Kinase-Promoted Serum Response Factor Phosphorylation

    doi: 10.34133/research.0815

    Figure Lengend Snippet: FGF21 activates p38 MAPK through the β-klotho (KLB)/FGFR1–transforming growth factor-β-activated kinase 1 (TAK1)–mitogen-activated protein kinase kinase 3/6 (MKK3/6) pathway. HASMCs were transfected with pCMV-HA or HA-FGF21 for 24 h, after which the cells were switched to complete medium for 24 h. The expression of p38 MAPK, p-p38 MAPK, FGFR1, p-FGFR1, and KLB in (A) or MKK3/6, p-MKK3/6, TAK1, and p-TAK1 in (D) was detected by Western blotting ( n = 3). (B and C) HASMCs were transfected with pCMV-HA or HA-FGF21 for 24 h. Then, the cells were treated with PD173074 (10 nmol/l) for 24 h. The expression of p-FGFR1, FGFR1, p-p38 MAPK, and p38 MAPK (B) and MYOCD, SRF, SMA, SM22α, and CNN1 (C) was determined by Western blotting ( n = 3). (E and F) After HA-FGF21 transfection for 24 h, HASMCs were treated with NG25 (10 μmol/l) for 24 h. The expression of p-TAK1, TAK1, p-MKK3/6, MKK3/6, p-p38 MAPK, and p38 MAPK (E) and SMA, SM22α, CNN1, MYOCD, and SRF (F) was determined by Western blotting ( n = 3). (G) HASMCs were transfected with HA-FGF21 for 24 h, followed by culture in complete medium for 24 h. The cell lysates were subjected to immunoprecipitation with anti-p-FGFR1 or anti-p-TAK1 antibodies. The pulled-down complexes and input cell lysates were analyzed by Western blotting with the anti-p-FGFR1 or anti-p-TAK1 antibodies. (H) Diagram of FGF21-activated p38 MAPK through the KLB/FGFR1–TAK1–MKK3/6 pathway. Data information: Data are expressed as mean ± SD. Student t test (2 groups) or 1-way ANOVA or 2-way ANOVA followed by Tukey’s test (more than 2 groups), * P < 0.05; ns, not significant.

    Article Snippet: We isolated plasma from blood samples, and the FGF21 level was measured using an ELISA kit (Cat. No. E-EL-H0074, Elabscience Biotechnology Co., Ltd.).

    Techniques: Transfection, Expressing, Western Blot, Immunoprecipitation

    p38 MAPK activation and efruxifermin improves intimal hyperplasia. (A to C) Female C57BL/6J or FGF21 −/− mice ( n = 8) were subjected to left carotid artery ligation and then intraperitoneally injected with the vehicle (distilled water), SB203580 (10 mg/kg), or anisomycin (15 mg/kg) every day, respectively, for 4 weeks. At the end of the experiment, carotid artery samples were collected and used for the following assays. HE staining for morphological analysis with quantitative analysis of neointima and media areas (A). The expression of SMA, SM22α (B), p38 MAPK, and p-p38 MAPK (C) in neointima areas was determined by immunofluorescence staining. (D to G) Left carotid artery ligation was performed on female C57BL/6J mice ( n = 8), which were then injected subcutaneously with physiological saline or efruxifermin (5 mg/kg) once a week for 4 weeks. At the end of the experiment, carotid artery samples were individually collected and used for the following assay: (D) HE staining for morphological analysis with quantitative analysis of neointima and media areas. (E to G) The expression of SMA and OPN (E), SRF and MYOCD (F), and p-p38 MAPK in SMA-positive cells (G) in neointimal areas was determined by immunofluorescence staining ( n = 5). Data information: Data are expressed as mean ± SD. Student t test (2 groups) or 2-way ANOVA followed by Tukey’s test, * P < 0.05.

    Journal: Research

    Article Title: Fibroblast Growth Factor 21 Promotes Vascular Smooth Muscle Cell Contractile Polarization via p38 Mitogen-Activated Protein Kinase-Promoted Serum Response Factor Phosphorylation

    doi: 10.34133/research.0815

    Figure Lengend Snippet: p38 MAPK activation and efruxifermin improves intimal hyperplasia. (A to C) Female C57BL/6J or FGF21 −/− mice ( n = 8) were subjected to left carotid artery ligation and then intraperitoneally injected with the vehicle (distilled water), SB203580 (10 mg/kg), or anisomycin (15 mg/kg) every day, respectively, for 4 weeks. At the end of the experiment, carotid artery samples were collected and used for the following assays. HE staining for morphological analysis with quantitative analysis of neointima and media areas (A). The expression of SMA, SM22α (B), p38 MAPK, and p-p38 MAPK (C) in neointima areas was determined by immunofluorescence staining. (D to G) Left carotid artery ligation was performed on female C57BL/6J mice ( n = 8), which were then injected subcutaneously with physiological saline or efruxifermin (5 mg/kg) once a week for 4 weeks. At the end of the experiment, carotid artery samples were individually collected and used for the following assay: (D) HE staining for morphological analysis with quantitative analysis of neointima and media areas. (E to G) The expression of SMA and OPN (E), SRF and MYOCD (F), and p-p38 MAPK in SMA-positive cells (G) in neointimal areas was determined by immunofluorescence staining ( n = 5). Data information: Data are expressed as mean ± SD. Student t test (2 groups) or 2-way ANOVA followed by Tukey’s test, * P < 0.05.

    Article Snippet: We isolated plasma from blood samples, and the FGF21 level was measured using an ELISA kit (Cat. No. E-EL-H0074, Elabscience Biotechnology Co., Ltd.).

    Techniques: Activation Assay, Ligation, Injection, Staining, Expressing, Immunofluorescence, Saline